Milk Thistle Extract - 300 mg - Silymarin 240 mg - 90 Capsules

Milk Thistle — 90 Capsules — Supports Healthy Liver Enzymes, Antioxidant Defense & Metabolic Balance*

LifeSource Vitamins Milk Thistle (Silymarin) provides a standardized extract from Silybum marianum to support healthy liver enzyme balance, cellular antioxidant defenses, and everyday wellness. Produced in FDA-registered, GMP-certified facilities and
3rd-party tested for identity, potency & purity.*

• Liver enzymes in NAFLD — Silybin–phosphatidylcholine + vitamin E improved ALT and metabolic markers (Study group: adults with biopsy-proven NAFLD • Loguercio • 2012).
(NIH/PubMed — 22343419)

• Insulin resistance & liver damage in NAFLD — Silybin–vitamin E–phospholipid complex showed improvements (Study group: adults with NAFLD • Federico • 2006).
(PMC — 1856214)

• NASH (high-dose silymarin) — Safety confirmed; exploratory fibrosis signals; mixed primary endpoints (Study group: adults with NASH • Navarro • 2019).
(NIH/PubMed — 31536511)

• NASH 48-week RCT — Primary NAS endpoint not met; well-tolerated; possible antifibrotic signal (Study group: adults with NASH • Kheong • 2017).
(NIH/PubMed — 28419855)

• Type 2 Diabetes — 4-month RCT improved glycemic profile vs placebo (Study group: adults with T2D • Huseini • 2006).
(NIH/PubMed — 17072885)

• T2D adjunct — Added to glibenclamide improved glycemic control in 120-day RCT (Study group: adults with T2D • Hussain • 2007).
(NIH/PubMed — 17887949)

• Diabetic nephropathy — Reduced albuminuria vs placebo on RAS blockade (Study group: T2D with macroalbuminuria • Fallahzadeh • 2012).
(NIH/PubMed — 22770926)

• Acute viral hepatitis — RCT assessed symptoms, labs, safety; generally well-tolerated (Study group: adults with acute hepatitis • El-Kamary • 2009).
(PMC — 2733865)

• Chronic HCV (high-dose) — No ALT benefit vs placebo; high-dose safety characterized (Study group: adults with chronic HCV • Fried • 2012).
(NIH/PubMed — 22797645)

• Alcohol-related cirrhosis (oxidative markers) — ↑GSH, ↓lipid peroxidation vs placebo at 6 months (Study group: adults with alcoholic cirrhosis • Lucena • 2002).
(NIH/PubMed — 11841050)

• Cirrhosis (historic RCT, survival signal) — Early trial suggested survival signal; later evidence mixed (Study group: alcoholic cirrhosis • Benda • 1980).
(NIH/PubMed — 7008367)

• NAFLD meta-analysis — Pooled RCTs associate silymarin with ALT/AST reductions (Scope: adults with NAFLD • Zhong • 2017).
(NIH/PubMed — 29245314)

• NAFLD systematic review (2024) — Signals for enzyme and histology improvements; calls for larger RCTs (Scope: NAFLD • Li • 2024).
(NIH/PubMed — 38579127)

• Chronic liver disease RCT (2024) — Reduced ALT/AST vs standard care; stronger effects in metabolic liver disease (Scope: CLD adults • Amjad • 2024).
(NIH/PubMed — 39850184)

• Diabetes & lipids review — Summarizes glycemic and lipid findings; safety profile (Scope: metabolic health • Xiao • 2020).
(PMC — 7535778)

• HCV community study (follow-up) — Symptom/well-being improvement; mixed virologic/biochemical outcomes (Scope: chronic HCV cohort • Strickland • 2005).
(NIH/PubMed — 15975544)

• Pharmacokinetics in HCV — Multiple-dose escalation characterized exposure at higher doses (Scope: chronic HCV • Hawke • 2010).
(NIH/PubMed — 19841158)

• University of Naples (Italy) — NAFLD improvements with silybin–vitamin E–phospholipids (Adults with NAFLD • Federico • 2006).
(PMC)

• NIH-funded U.S. centers — High-dose silymarin studies in NASH/HCV clarified safety & histology endpoints (Adults with NASH/HCV • Navarro • 2019; Fried • 2012).
(NIH/PubMed)(NIH/PubMed)

• University of Granada (Spain) — Antiperoxidative effects in alcoholic cirrhosis RCT (Adults with alcoholic cirrhosis • Lucena • 2002).
(NIH/PubMed)

• University of Tehran & collaborators — T2D RCTs reporting glycemic benefits (Adults with T2D • Huseini • 2006; Hussain • 2007).
(NIH/PubMed)(NIH/PubMed)

• World Health Organization (WHO) — Monograph on Silybum marianum (quality, safety, usage context) (Monograph • WHO).
(WHO PDF)

• European Medicines Agency (EMA/HMPC) — Assessment report for milk thistle fruit preparations (Regulatory review • 2018).
(EMA PDF)

• NCCIH (NIH) — Milk thistle fact sheet (mixed evidence, safety notes, research gaps) (Fact sheet • 2024 update).
(NCCIH)

• NIH/NLM LiverTox — Safety profile summary (rare to no hepatotoxicity) (Reference • 2020).
(LiverTox)

• Supports healthy liver enzyme balance (ALT/AST) in adults*

• Helps defend cells from oxidative stress*

• Supports metabolic balance and everyday wellness*

• Gentle, well-tolerated herbal support*

• 3rd-party lab tested for identity, potency & purity

Suggested Use

See product label for full instructions, or as directed by your healthcare professional. Do not exceed recommended dose. If pregnant, nursing, taking medications, or have a medical condition, consult your physician.*

Product Specifications

• Form — Easy-to-swallow capsules

• Serving Size — See Supplement Facts label

• Servings Per Container — See Supplement Facts label

• Free From — Non-GMO, gluten-free; no artificial colors, preservatives or synthetic chemicals*

• Quality — Third-party tested for identity, potency & purity

Key Ingredients

Milk Thistle Extract — Concentrated flavonolignans that support antioxidant defenses and healthy liver enzyme balance.*

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Silymarin (Milk Thistle) — supports healthy liver enzymes, antioxidant defense & metabolic balance. 3rd-party tested quality. Clinically Studied Ingredients — NIH/PubMed!*